Xue Gaici, Zhou Yu, Liu Peng, Zuo Qiao, Yang Pengfei, Fang Yibin, Li Qiang, Zhao Rui, Xu Yi, Hong Bo, Huang Qinghai, Liu Jianmin
Department of Neurosurgery, General Hospital of Southern Theatre Command of PLA, Guangzhou, China.
Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, China.
Front Neurol. 2021 Jan 28;11:631745. doi: 10.3389/fneur.2020.631745. eCollection 2020.
Stenting in ruptured middle cerebral artery (MCA) aneurysms was reported with a high perioperative complication rate. However, the treatment devices and physician's experience have continued to evolve. We performed this retrospective study to evaluate the safety and efficacy of LVIS stent-assisted coiling for ruptured MCA aneurysms. Patients with acutely ruptured MCA aneurysms treated between November 2014 and October 2019 were retrospectively reviewed. Clinical and angiographic data of those treated with LVIS stents were collected from a prospectively maintained database. A total of 40 patients with 40 ruptured MCA aneurysms were enrolled, which comprised 26.3% (40/152) of all the ruptured MCA aneurysms at the same time. All stents were successfully deployed except for one (2.5%), which had a poor stent opening. Ischemic procedure-related complications were encountered in three patients (7.5%). One patient died of complications related to high-grade SAH on admission. Follow-up (mean 15.9 months) angiography was performed for 36 patients, which showed 33 (91.7%) aneurysms were completely occluded, 1 (2.8%) was improved, 1 (2.8%) was stable, and 1 (2.8%) was recanalized. Clinical follow-up (mean 29.6 months) was available for all survived patients, which showed 38 (95.0%) patients had favorable neurologic outcomes (mRS score 0-2), and 2 (5.0%) patients had poor neurologic outcomes. The use of LVIS stents is feasible, safe, and effective with glycoprotein IIb/IIIa inhibitor for the treatment of ruptured MCA aneurysms in the acute setting. Prospective, multicenter studies with larger sample sizes are still required to further evaluate the safety and long-term efficacy.
据报道,大脑中动脉(MCA)破裂动脉瘤的支架置入术围手术期并发症发生率较高。然而,治疗设备和医生的经验一直在不断发展。我们进行了这项回顾性研究,以评估LVIS支架辅助弹簧圈栓塞术治疗破裂MCA动脉瘤的安全性和有效性。对2014年11月至2019年10月期间接受急性破裂MCA动脉瘤治疗的患者进行了回顾性分析。从一个前瞻性维护的数据库中收集了接受LVIS支架治疗患者的临床和血管造影数据。共纳入40例患有40个破裂MCA动脉瘤的患者,占同期所有破裂MCA动脉瘤的26.3%(40/152)。除1例(2.5%)支架展开不佳外,所有支架均成功置入。3例患者(7.5%)出现与缺血相关的手术并发症。1例患者因入院时与高级别蛛网膜下腔出血相关的并发症死亡。对36例患者进行了随访(平均15.9个月)血管造影,结果显示33个(91.7%)动脉瘤完全闭塞,1个(2.8%)有所改善,1个(2.8%)稳定,1个(2.8%)再通。所有存活患者均进行了临床随访(平均29.6个月),结果显示38例(95.0%)患者神经功能预后良好(mRS评分0-2),2例(5.0%)患者神经功能预后较差。在急性情况下,使用LVIS支架联合糖蛋白IIb/IIIa抑制剂治疗破裂MCA动脉瘤是可行、安全且有效的。仍需要进行前瞻性、多中心、大样本量研究以进一步评估其安全性和长期疗效。